Saturday, August 29, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Approves Mimrylo for Polycythemia VeratodayDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue4 weeks agoHEALTHCARE & FDAFDA Authorizes Generic Bimectin for Screwworm PreventiontodayDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue4 weeks agoHEALTHCARE & FDAFDA Opens GenAI Medical Device Regulation to Public InputtodayMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue4 weeks agoHEALTHCARE & FDATrump Admin Blocks $1.6B in Fraudulent Medicare Lab PaymentstodayENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors4 weeks agoTECHNHTSA Extends Comment Period on Vehicle Safety ExemptionstodaySEARCH DEMANDCasgevy List Price: $2.2 Million4 weeks agoENERGYBLM Launches 30-Year Permit for Trans-Alaska Pipeline OperationsyesterdaySEARCH DEMANDData Center Power Exchange4 weeks agoMARKETSFTC Blocks Henkel's $725M Liquid Nails Bid—Antitrust WinsyesterdayTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall4 weeks agoHEALTHCARE & FDAFDA Approves First RAS Inhibitor for Pancreatic Cancer2 days agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing4 weeks agoDEFENSEBoeing Lands $131B F-15 Contract—Fighter Jet Dominance2 days agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win4 weeks agoHEALTHCARE & FDACostco Enters Medicare Advantage—Retail Disruption Looms2 days agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue4 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariffs Take Effect—Retailers Brace2 days agoWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market4 weeks agoTRADE & TARIFFSU.S. Rolls Out Iran Sanctions—Oil Prices Slip2 days agoHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption4 weeks agoHEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA Nod3 days agoENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risk4 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia Approval3 days agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeeze3 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle Boost3 days agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win3 weeks agoTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price Cuts3 days agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure3 weeks agoTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price Pressure3 days agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief3 weeks agoWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance Shift4 days agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestone3 weeks agoHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage Eases4 days agoDEFENSERising Defense Spending Lifts Northrop Grumman Outlook3 weeks agoWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance Costs4 days agoMARKETSFTC Threatens Booking Holdings Over Priceline Practices3 weeks agoWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut Compliance4 days agoHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practices3 weeks agoTECHCHIPS Act Transforms Binghamton Into Semiconductor Hub5 days agoHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma3 weeks agoTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctions5 days agoTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout3 weeks agoTECHUtah Governor Signs Quantum Computing Initiative Order5 days agoTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing3 weeks agoDEFENSEFAA Engine Inspection Order Lifts MRO Stocks6 days agoWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers3 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings6 days agoENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes3 weeks agoHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demand6 days agoDEFENSEPentagon Awards Space-Based Target Tracking Contracts3 weeks agoTECHD-Wave Wins Canadian Quantum Funding for Annealing6 days agoTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio3 weeks agoENERGYEnbridge Wins Federal Permit for Line 5 Tunnellast weekWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty3 weeks agoENERGYFederal Court Orders Enbridge Line 5 Removallast weekDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains3 weeks agoWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Personslast weekWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift3 weeks agoHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpaymentlast weekWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing2 weeks agoENERGYNewsom Passes Diablo Canyon Decision to Successorlast weekHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance2 weeks agoDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervaluedlast weekENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask2 weeks agoTECHCommerce Eases Drone Export Rules—U.S. Makers Winlast weekHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock2 weeks agoHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnosticslast weekDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract2 weeks agoHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopolylast weekTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility2 weeks agoDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfalllast weekDEFENSEBlackSky Lands Multi-Year Satellite Contract2 weeks agoENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Easeslast weekHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Wins2 weeks agoWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demandlast weekTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makers2 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressurelast weekTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refund2 weeks agoTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boostlast weekCRYPTOSEC Delays Crypto Rules—Uncertainty Persists2 weeks agoENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Pathlast weekTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earningslast week
Healthcare & FDA

FDA Approves Mimrylo for Polycythemia Vera

First hepcidin-mimicking drug opens niche market for rare blood disorder treatment.

Image: Money Racket
By at Money Racket · Aug 29, 2026

The FDA approved Mimrylo (rusfertide) on August 28, 2026, marking the first treatment for polycythemia vera that mimics hepcidin, a hormone regulating iron in the body. The drug targets patients whose disease remains uncontrolled by existing therapies by limiting iron availability and reducing red blood cell overproduction.

Reata's first-in-class hepcidin mimic opens a new revenue stream in a rare-disease niche where competitors already own the market.

The direct beneficiary is Reata Pharmaceuticals (RETA), which developed Mimrylo. The approval validates its rare-disease pipeline and opens a revenue stream in a patient population previously limited to phlebotomy, hydroxyurea, and JAK inhibitors. Reata is a small-cap biotech with meaningful upside from a first-in-class label.

Competitors face modest pressure. Incyte (INCY), which markets ruxolitinib (Jakafi) for polycythemia vera, and Geron (GERN), which sells imetelstat (Tasodelstat), now compete for a slice of an expanding but still-small patient pool. Neither faces material revenue risk; the rare-disease market is large enough for multiple players, and switching costs are high.

Watch for uptake data in Q4 2026 and 2027. Reata's stock will hinge on real-world adoption rates, insurance coverage decisions, and whether Mimrylo captures treatment-resistant patients or cannibalizes existing therapies. Analyst commentary on market penetration will signal whether this is a niche win or a franchise builder.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Knowing who cashed in is only half the trade.

Every catalyst has a second move — the supplier, the sector, the part already priced in. Money Racket Pro hands you that read on every policy event, plus the pre-market brief six mornings a week, before the open.

Get the edge · $40/mo

Join the readers who get there before the financial press. Cancel anytime, one click.

Share

https://moneyracket.com/article/fda-approves-mimrylo-polycythemia-vera/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →